SCHEMBL13429337

SCHEMBL13429337

CC(Nc1cccc(Oc2cc(=O)[nH]c3ccccc23)c1)c1ccncc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.45
KDM4E B2RXH2 3/20 0.40
PTK6 Q13882 2/20 0.39
KMT2A Q03164 2/20 0.39
BRAF P15056 3/20 0.37
USP2 O75604 1/20 0.37
LRRK2 Q5S007 1/20 0.37
GRM5 P41594 1/20 0.36
ROCK1 Q13464 2/20 0.36
AURKB Q96GD4 2/20 0.36
ALDH1A1 P00352 2/20 0.36
HSD17B10 Q99714 2/20 0.36
DCLK1 O15075 1/20 0.36
ROCK2 O75116 1/20 0.36
CHEK2 O96017 1/20 0.36
GSK3A P49840 1/20 0.36
GSK3B P49841 1/20 0.36
IRAK1 P51617 1/20 0.36
PRKX P51817 1/20 0.36
NEK4 P51957 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13429334 0.89 KDM4E (0.48) KDM4EPTK6KMT2ABRAFUSP2
SCHEMBL13429262 0.79 F2 (0.46) GAAKDM4EPTK6KMT2ABRAF
SCHEMBL13429184 0.77 GRIN2D (0.45) KDM4EGRM5ALDH1A1GSK3BHPGD
SCHEMBL13429178 0.73 HPGD (0.44) KDM4EGRM5ALDH1A1GSK3BHPGD
SCHEMBL3214639 0.73 SMN1; SMN2 (0.49) GAAKDM4EPTK6KMT2ABRAF
SCHEMBL13429381 0.73 MEN1 (0.44) GAAPTK6KMT2ABRAFGRM5
SCHEMBL13429069 0.72 CYP1A2 (0.53) GAAKDM4EKMT2AUSP2GRM5
SCHEMBL13429074 0.72 ABCG2 (0.51) GAAKDM4EKMT2AALDH1A1HSD17B10
SCHEMBL13429256 0.72 MAOA (0.44) GAAKDM4EPTK6KMT2ABRAF
SCHEMBL13429313 0.72 GAA (0.53) GAAPTK6KMT2AALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS WYETH (US) 2010-03-18 US disclosed
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS WYETH (US) 2010-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS MTOR, RICTOR, PIK3CA GAA 1227/4885KDM4E 728/4885PTK6 146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.